Prenumeration
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
On Monday Dec 11 Ziccum presents as special guest at a live scientific webinar on ‘Inhaled Biologics’ with inhalation Key Opinion Leader Assoc. Prof. Per Gerde. New Ziccum COO Xavier Turon will present the company at the webinar, which addresses formulation scientists working on new, more stable formulations of biopharmaceuticals.
Register for the Webinar here.
The webinar will cover:
- how LaminarPace, Ziccum’s Mass Transfer technology, uniquely formulates and dries biologics, without exposing them to extreme temperatures, as stable, bioactive dry powders that are highly suited for inhalation
- Preclinical Testing solutions for Inhalable Formulations.
The Webinar is part of a series for industry developers hosted by Inhalation Sciences AB. This session, part of that series, is titled “INHALED BIOLOGICS: Realization and Preclinical Testing of Dry Powder Formulations”.
Inhalable solid dose forms of biologics including next-generation mRNA vaccines are of great interest to the biopharmaceutic industry at the moment, promising increased storage stability, simplified patient administration and an ability to stimulate the mucosal immune system. LaminarPace was originally developed by Associate Professor Gerde specifically to dry liquid biologics for inhalation.